Capital Fund Management (CFM)’s Viking Therapeutics VKTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$351K	Sell	10,800 -25,300	-70%	-$813K	﹤0.01%	1930
2025 Q4	$1.27M	Buy	36,100 +21,100	+141%	+$748K	﹤0.01%	1913
2025 Q3	$394K	Sell	15,000 -8,800	-37%	-$263K	﹤0.01%	2345
2025 Q2	$631K	Sell	23,800 -11,500	-33%	-$303K	﹤0.01%	2146
2025 Q1	$852K	Buy	35,300 +14,100	+67%	+$446K	﹤0.01%	1722
2024 Q4	$853K	Buy	+21,200	New	+$1.21M	﹤0.01%	1806
2024 Q2	–	Sell	-15,000	Closed	-$1.23M	–	2192
2024 Q1	$1.23M	Sell	15,000 -9,400	-39%	-$418K	﹤0.01%	1635
2023 Q4	$454K	Buy	+24,400	New	+$319K	﹤0.01%	2005

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital Fund Management (CFM)'s VKTX Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Viking Therapeutics (VKTX) stake by 78% in Q1 2026, buying an estimated $292K and bringing the position to 20,824 shares worth $678K. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

Capital Fund Management (CFM) first reported a position in VKTX in Q4 2019 and has held it in 8 quarters since. The position peaked at $4.92M in Q4 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Capital Fund Management (CFM) held 20,824 shares of Viking Therapeutics worth $678K as of Q1 2026.
Capital Fund Management (CFM) bought 9,098 Viking Therapeutics shares in Q1 2026, an estimated $292K.
Viking Therapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #1809 holding.
Capital Fund Management (CFM) first reported a position in Viking Therapeutics in Q4 2019 and has held it in 8 quarters since.
Capital Fund Management (CFM)'s Viking Therapeutics position peaked at $4.92M in Q4 2023.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.